Sumitomo Pharma Co., Ltd.
【Sumitomo Pharma】Fiscal Year 2025 Financial Results | Sales of 533 billion yen (+19.1% YoY)
Sumitomo Pharma achieved sales of 533 billion yen (up 19.1% YoY) in fiscal year 2025, with operating profit significantly increased to approximately 107 billion yen. Overseas sales ratio also expanded to 81.6%, strengthening the future growth foundation.
Key Figures
- Sales Revenue: 4,533 hundred million yen（前年比+19.1%）
- Net Income Attributable to Owners of Parent: 1,069 hundred million yen（前年比+352.2%）
- Core Operating Income: 1,059 hundred million yen（前年比+145.4%）
AI要約
Business Performance Overview
In fiscal year 2025, Sumitomo Pharma’s sales revenue expanded to 4,533 billion yen (up 19.1% YoY), with core operating income reaching 1,059 billion yen (up 145.4%), marking a record high. The overseas sales ratio remained high at 81.6%, with notable growth predominantly in North America. Net income also saw a substantial increase to 1,069 billion yen, enhancing profitability and global competitiveness.
Future Outlook and Shareholder Impact
The company plans to further strengthen overseas expansion, with sustained growth expected in sales and profits driven by new drug development and pipeline progress. R&D expenses are also on the rise, aiming to launch innovative pharmaceuticals. As part of shareholder return strategies, possible dividends and share buybacks are under consideration, positioning the company as an attractive growth investment.
Sales Revenue Trend
Operating Income Trend
Segment Revenue Breakdown
Gross Profit Margin
Forecast vs. Actual
Sumitomo Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
